Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sandoz to Take Over Astellas’ Japan MA for Funguard from June-End
May 21, 2024
- Towa, Sawai See Continued Growth in Japan in FY2024 amid New WPP Strategies
May 20, 2024
- Pfizer Rolls Out Single-Dose Version of COVID-19 Vaccine in Japan
May 20, 2024
- Keytruda Gets Nod for Gastric, Biliary Tract Cancer in Japan
May 20, 2024
- Prevymis Now Approved for CMV Prevention in Organ Transplant Recipients in Japan
May 20, 2024
- Braftovi-Mektovi Combo Broadens Label to Thyroid Cancer: Ono
May 20, 2024
- Amylyx Pulls Out from Japan after ALS Trial Flop
May 20, 2024
- Mitsubishi Tanabe’s Earnings Sink 2-Digits in FY2023 on Backlash from Previous Gilenya Royalties
May 17, 2024
- Eisai to Appoint CEO’s Son for Representative Post in Prelude to Succession
May 17, 2024
- Ultragenyx’s Evkeeza Gets Label Update to Allow Use under Age 5
May 17, 2024
- No Clenafin Generic Competition until June 2025: Kaken
May 17, 2024
- Japan Generic Market Set to Surpass 1.6 Trillion Yen by 2032: Fuji Keizai
May 17, 2024
- Xocova Forerunner in March GP Rep Promotion Rankings: Intage
May 17, 2024
- Eisai Begins Rolling Submission for Subcutaneous Leqembi in US
May 16, 2024
- Eisai Sees Global Sales of Leqembi Surging to 56.5 Billion Yen in FY2024
May 16, 2024
- Mounjaro Going Back to Normal Supply from June: Lilly/Mitsubishi
May 16, 2024
- Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
- Sanofi Files Sarclisa as 1st-Line Quad Therapy for MM in Japan
May 15, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…